Accellta
Accellta provides custom-made solutions for mass production of high quality human embryonic and induced pluripotent stem cells, progenitors and differentiated cells for drug discovery, regenerative medicine and research. Culturing is conducted in 3D suspension systems under feeder-free, adherent-free and xeno-free conditions. The tailored solutions dramatically reduce production time and costs.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Clinical Services
- Market Focus:
- Nationally (across the country)
This company also provides solutions for other industrial applications.
Please, visit the following links for more info:
Why Accellta ?
Accellta offers a range of revolutionary solutions for better affordability and quality of stem cell culturing. Accellta's technologies are the result of over 15 years of pioneering research and development at the Stem Cell Center in the Technion’s Rappaport Faculty of Medicine.
Maxells - The Power of Suspension Culturing
Maxells, Accellta’s novel solution for industrialization of embryonic and induced pluripotent stem cell culturing, is based on dynamic culturing of stem cells in suspension without microcarriers. Maxells allows uniform cell growth and improved cell differentiation and delivers unprecedented scalability and quality. Maxells enables cost-effective mass production of stem cells for therapeutic purposes, banking and R&D applications.
Singles - Superior Uniformity and Optimal Scalability
'Singles' is a breakthrough technology that offers a simple and effective way to culture pluripotent stem cells as single-cells in suspension, serving as a platform for genetic manipulation of the cells and providing enhanced uniformity and purity.
Top Quality Cells and Methods
Accellta offers a variety of NIH-registered highly characterized ES and iPS cell lines. In addition, we offer protocols for feeder-free, xeno-free culturing.
The Power of Partnering
Accellta is looking for strategic partnerships with the goal of leveraging its technology for custom-made industrial and clinical requirements.
Intellectual Property
The intellectual property assets of Accellta include a portfolio of patents pertaining to novel techniques and products, including:
- Pluripotent stem Cell culturing
- Human foreskin-derived feeder cells
- Growth media for feeder-free culturing of hPSC
- Stem Cell expansion in suspension
- Stem Cell culturing as single-cells in bioreactors
- Stem-Cell controlled differentiation
- Medium formulation